Moleculin Net Income Trend from 2010 to 2022

MBRX
 Stock
  

USD 1.65  0.12  7.84%   

Moleculin Biotech Net Income yearly trend continues to be fairly stable with very little volatility. Net Income will likely drop to -16,312,263 in 2022. . Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.
  
Refresh
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin main balance sheet or income statement drivers, such as Interest Expense of 39.7 K, Operating Expenses of 18.6 M or Research and Development Expense of 11.6 M, as well as many exotic indicators such as Total Assets Per Share of 3.74, Quick Ratio of 18.85 or Net Current Assets as percentage of Total Assets of 88.37. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules. It can also supplement various Moleculin Biotech Technical models. Additionally, see the analysis of Moleculin Biotech Correlation against competitors.

Moleculin Net Income Breakdown

Showing smoothed Net Income of Moleculin Biotech CS with missing and latest data points interpolated. Net income is one of the most important fundamental items in finance. It plays a large role in Moleculin Biotech financial statement analysis. It represents the amount of money remaining after all of Moleculin Biotech CS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.Moleculin Biotech's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (15.89 M)10 Years Trend
Decreasing
Slightly volatile
 Net Income 
Share
      Timeline 

Moleculin Net Income Regression Statistics

Arithmetic Mean(7,521,885)
Coefficient Of Variation(88.17)
Mean Deviation 6,048,608
Median(3,926,000)
Standard Deviation 6,632,258
Range 16,989,189
R-Value(0.91)
R-Squared 0.84
Significance 0.00001219
Slope(1,557,077)

Moleculin Net Income History

2015-365.8 K
2016-3.9 M
2017-9.8 M
2018-11.9 M
2019-13.2 M
2020-17.4 M
2021-15.9 M
2022-16.3 M

Other Fundumenentals of Moleculin Biotech

Moleculin Biotech Net Income component correlations

About Moleculin Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moleculin Biotech income statement, its balance sheet, and the statement of cash flows. Moleculin Biotech investors use historical funamental indicators, such as Moleculin Biotech's Net Income, to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moleculin Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Income-15.9 M-16.3 M
Net Income Common Stock-15.9 M-16.3 M
Net Income Per Employee-934.9 K-1 M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now

   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moleculin Biotech Correlation against competitors. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
43.7 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.